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 IGFBP-5 enhances epithelial cell adhesion and protects epithelial 
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Summary 
 TGFE is a major fibrotic factor and its actions involve induction of epithelial cell 
death, together with the stimulation and transdifferentiation of fibroblasts into 
collagen- and fibronectin-secreting myofibroblasts. These actions of TGFE are also 
consistent with a pro-metastatic role, by aiding epithelial cell escape through 
mesenchymal tissues. Recently IGFBP-5 has been described as a pro-fibrotic (pro-
metastatic?) agent and the aim of this study was to compare and contrast the actions 
of IGFBP-5 with TGFE. We used NMuMG cells and cloned stable epithelial and 
mesenchymal lines from the parent cells. TGFE induced apoptosis and/or EMT in 
the epithelial cells, whereas it enhanced mesenchymal cell survival and migration. 
IGFBP-5, in contrast, enhanced both cell-cell and cell-ECM adhesion and also 
improved wound closure in epithelial cells whereas, in mesenchymal cells, IGFBP-5 
decreased adhesion and migration. Furthermore, IGFBP-5 was able to antagonise the 
actions of TGFE. In a co-culture model simulating epithelial-mesenchymal 
boundaries, IGFBP-5 was able to antagonise the disruptive transgressions induced by 
TGFE. Overall, these findings suggest that IGFBP-5 is important in maintaining 
epithelial-mesenchymal boundaries and thus may limit metastasis and fibrosis by 
inducing an orderly repair mechanism, very distinct from the fibrotic disruption 
induced by TGFE. A role for IGFBP-5 in the inhibition of metastasis is supported by 
immunohistochemical studies of breast cancer microarrays, where we show that 
elevated IGFBP-5 expression is associated with increased disease-free survival. 
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Introduction 
Tissue boundaries must be formed and maintained, despite a range of traumatic 
insults, such as the wound healing process, which can ultimately manifest itself in a 
variety of chronic fibrotic disorders, where healing remains unresolved (Wynn and 
Ramalingam, 2012) or metastasis, where epithelial cells cross mesenchymal tissues 
and endothelial barriers.  
The principal agent driving EMT is TGF-ȕ1 (Margadant and Sonnenberg, 2010). 
TGFE induces apoptosis in epithelial cells but can also induce EMT in the surviving 
cells. Thus, although TGFE is thought to be protective in the early stages of tumour 
formation (pro-apoptotic) it is a poor prognostic factor during metastatic disease (pro-
EMT) (Roberts and Wakefield, 2003, Siegel and Massague, 2003). By increasing 
collagen and fibronectin production from fibroblasts and inducing their trans-
differentiation into myofibroblasts, TGF-ȕ1 acts to disrupt the epithelial-
mesenchymal boundary, generating a fibrotic response which impairs wound healing 
(Nakerakanti and Trojanowska, 2012). Insulin-like growth factor binding protein-5 
(IGFBP-5) is  increased in fibrotic disorders (Feghali and Wright, 1999, Zuo et al. , 
2002) and induces fibrotic responses similar to  TGF-ȕ1 (Yasuoka et al. , 2006a, 
Yasuoka et al. , 2008, Yasuoka et al. , 2006b). However, we believe that IGFBP-5 and 
TGF-ȕ1 serve very different functions. For example, we have demonstrated that 
IGFBP-5 increases epithelial cell adhesion to the ECM, whilst simultaneously 
inhibiting migration by maintaining E-cadherin expression (Sureshbabu et al. , 2012). 
These responses to IGFBP-5 would be anticipated to reduce, rather than increase, 
metastatic potential and to limit fibrotic responses to the mesenchymal compartment 
by maintaining an effective epithelial barrier. Paradoxically, increased IGFBP-5 
expression has been associated with poor prognosis during metastasis (Hou et al. , 
2009, Huynh, 1998, McGuire et al. , 1994, Mita et al. , 2007, Pekonen et al. , 1992). 
Rather than inducing metastasis however, we believe that IGFBP-5 secretion might 
actually reflect a host response to limit tumour escape.  
To test this hypothesis, we compared the actions of TGFE and IGFBP-5, exploring 
their individual roles in the maintenance of the epithelial-mesenchymal boundary. We 
took advantage of a normal mouse mammary cell line (NMuMG), where epithelial 
cells exhibit both apoptosis and EMT in response to TGFE. Furthermore, this cell 
line has previously been used to generate both epithelial and mesenchymal clones 
(Maeda et al. , 2005) which allowed the actions of these growth factors to be 
examined in different phenotypic states of the same cell line.  We describe actions of 
IGFBP-5 which suggest a role as a natural antagonist of TGF-ȕ1 in the epithelial 
compartment, which would be anticipated to improve wound healing responses and to 
limit metastatic escape of epithelial cells. We also investigated if this was clinically 
relevant by assessing the prognostic significance of IGFBP-5 in a cohort of human 
breast cancer specimens. 
 
Results: 
Generation of epithelial and mesenchymal clones of NMuMG cells 
Using a limiting-dilution technique, we were able to clone stable lines which 
exhibited either epithelial or mesenchymal characteristics (Figure 1). Epithelial clones 
were easily identifiable by the tight colonies formed, whereas there was an absence of 
such interaction in the mesenchymal lines (Figure 1A). In the epithelial clones, F-
actin was arranged around the periphery of the cell, whereas it was evident as stress 
fibres in the mesenchymal clones (Figure 1B). The differences in phenotype were 
confirmed by demonstrating E-cadherin expression in the epithelial clones but not the 
mesenchymal clones (Figure 1C), whilst the mesenchymal clones exhibited staining 
for collagen (Figure 1D) and fibronectin (Figure 1E), which the epithelial clones did 
not. When the cells were co-cultured by seeding as a mixture, the cells arranged 
themselves with epithelial colonies surrounded by mesenchymal cells (Figure 1F). 
When cultured on matrigel, to encourage 3D growth, the epithelial clones formed 
characteristic spheroids, whereas the mesenchymal clones developed structures more 
closely resembling ductal or tubular structures (Figure 1G). When mixed, the cells 
organised themselves into spheroids, linked by mesenchymal duct-like structures 
(Figure 1H). Because the mesenchymal cells were apparently derived from the 
original parent cell and the possibility existed of a mesenchymal-epithelial transition 
(MET), which could make interpretation difficult in some of our co-culture 
experiments, some studies were also undertaken with a classic mesenchymal cell, the 
3T3 fibroblast, which does not undergo MET. 3T3 cells also exhibited abundant 
collagen expression (see Figure 6), which could be used as a reliable marker for their 
identification in culture. 
Responses of NMuMG cells to TGF , IGF-I and insulin 
We undertook some initial studies to characterise the response of both epithelial and 
mesenchymal clones to TGFE as well as to IGF-I, which acts as a major survival 
factor for these cells. We also used insulin as a surrogate IGF-I because it is incapable 
of interaction with IGFBP-5 and can thus be used to help distinguish IGF-dependent 
and IGF-independent effects of IGFBP-5. 
In order to examine the effects of growth factors, the cells were cultured in low (2%) 
serum, sufficient to allow the cells to adhere but limiting their survival and 
proliferative potential. By day 3, cell numbers were decreased by approximately 50% 
in control wells of both epithelial and mesenchymal cells. IGF-I and insulin prevented 
the decrease in cell numbers of epithelial and mesenchymal clones (Figure 2A). In 
contrast, although TGFE also inhibited the decrease in cell numbers of mesenchymal 
clones, it led to an even greater decrease in epithelial cells than in control wells, 
resulting in an 80%decrease in epithelial cell numbers. 
When we examined the actions of TGFE on epithelial clones, it was evident that the 
surviving cells had undergone a phenotypic epithelial-mesenchymal transition (EMT) 
(Figure 2B) which involved down-regulation of E-cadherin expression (Figure 2C), 
an effect which could be prevented by the TGFE antagonist, BMP-7. 
These results provided us with confidence that these clones would be suitable to 
examine the actions of IGFBP-5, in order to compare and contrast them with TGFE 
in epithelial and mesenchymal cell lines. 
Effects of IGFBP-5 on adhesion of epithelial clones 
Based upon our previous studies which had demonstrated that IGFBP-5 could 
enhance adhesion of MCF-7 epithelial cells to both collagen and fibronectin, as well 
as other provisional matrices (Sureshbabu, Okajima, 2012), we conducted short-term 
(30 min) experiments in serum-free conditions. IGFBP-5 potently enhanced the 
adhesion of epithelial clones to the substratum and this was particularly pronounced 
for collagen and fibronectin, when compared with laminin (Figure 3A, B).  
Epithelial clones survived poorly in serum-free conditions during prolonged 
(overnight) culture and this was evident from the fact that untreated cells showed little 
or no interaction with each other or adhesion to the substratum. Metabolic activity, 
judged by WST-1 activity was also very low (results not shown). In contrast both 
insulin and IGF-I stimulated considerable cell-cell adhesion, generating 
metabolically-active spheroids (Figure 3C). To our surprise, IGFBP-5, despite having 
initially induced adhesion to the substratum, also induced the formation of spheroids. 
Quantification of spheroid number and size revealed that both IGF-I and insulin 
increased spheroid size, whereas IGFBP-5 increased spheroid numbers (Figure 3D). 
Intriguingly, when cells were treated with both IGF-I and IGFBP-5 (in approximately 
equimolar concentrations), neither the number or size of spheroids was increased 
compared with controls, suggesting that they neutralised each other. This begs the 
question “Which factor inhibits which?” Support for independent actions of IGF-I and 
IGFBP-5 on NMuMG epithelial clones came from co-incubation of IGFBP-5 and 
insulin (which do not interact with each other). This resulted in the formation of even 
larger spheroids. TGFEcompletely inhibited the formation of spheroids. Thus, in 
stark contrast to TGFE, IGFBP-5 supported epithelial cell survival, apparently by 
driving both cell adhesion and cell-cell contact. Furthermore, when epithelial cells 
were cultured in the presence of serum to allow attachment and survival, IGFBP-5, 
expressed from an adenoviral construct, was able to partially inhibit the apoptotic 
effects of TGFE (Figure 3E). IGFBP-5 could also limit the epithelial-mesenchymal 
transition induced by TGFE1. IGFBP-5 had no effect on actin arrangement on its 
own, with cells showing the characteristic epithelial expression of actin around the 
plasma membrane (Figure 3F upper panel). In contrast, TGFE1 induced re-alignment 
of actin into stress fibres and led to dramatic elongation and alignment of cells. 
Although actin re-arrangement was also evident with the combined treatment of 
TGFE1 and IGFBP-5, cell alignment and elongation were considerably reduced. 
However, IGFBP-5 was unable to prevent the down-regulation of E-cadherin  induced 
by TGFE1 (Figure 3F lower panel) indicating that it was, at best, a partial antagonist 
of this action of TGFE1. 
Actions of IGFBP-5 on adhesion in mesenchymal cells 
When IGFBP-5 was used to treat mesenchymal clones of NMuMG cells or 3T3 cells, 
there was a remarkable decrease in cell adhesion to laminin, fibronectin or collagen 
(Figure 3G,H) which was not evident in response to TGFE. The initial action of 
IGFBP-5, however, was to induce mesenchymal cells to migrate towards each other, 
again forming small spheroids (Figure 3I – arrowheads). These structures did not, 
however, survive fixation and washing procedures. Once again, this action was 
distinct from that of TGFȕ1, which induced mesenchymal cell survival, characterised 
by increased cell numbers, cell elongation and swirling patterns, characteristic of 
myofibroblast trans-differentiation (Figure 3I). When TGFE and IGFBP-5 were 
added together, the effect of IGFBP-5 pre-dominated over the actions of TGFE 
(Figure 3J). 
Mechanism of action of IGFBP-5 
In order to assess the role of intracellular signalling in the actions of IGFBP-5, we 
utilised a variety of kinase inhibitors. The actions of IGFBP-5 on epithelial spheroid 
formation were unaffected by any of the classical kinase inhibitors tested (Figure 4A). 
In contrast, the action of TGFE on epithelial cells was, as expected, blocked by the 
inhibitors of the type I receptors ALK4/5/7, A.8301 and SB431542  (Figure 4B). 
TGFE increased phosphorylation of Smad 2/3, whereas IGFBP-5 had no effect, 
either alone or in combination with TGFE (Figure 4C) The de-adhesive action of 
IGFBP-5 on mesenchymal clones was also unaffected by any of the kinase inhibitors 
tested although the PI3-kinase inhibitor LY294002 also inhibited cell adhesion alone, 
so no definitive conclusion could be made about PI3-kinase and IGFBP-5 (Figure 
4D,E). 
Effects of IGFBP-5 and TGF  on wound closure 
Effects of IGFBP-5 and TGFE on wound closure were examined either alone, or in 
combination, using ibidi 2-chamber migration inserts. TGFE inhibited epithelial 
wound closure (Figure 5A, C), whereas it enhanced wound closure in mesenchymal 
cells (Figure 5B, D). In contrast, IGFBP-5 enhanced wound closure of epithelial cells, 
either alone or in combination with TGFE (Figure 5A, C), but significantly 
antagonised the effect of TGFE in mesenchymal clones, although it had no effect 
alone.  
Effects of IGFBP-5 and TGF  on maintenance of epithelial-mesenchymal 
boundaries. 
We next examined the ability of IGFBP-5 and TGFE to influence boundary 
formation between epithelial NMuMG clones and 3T3 fibroblasts. 3T3 fibroblasts 
were used to avoid potential MET transformations that might be induced in the 
mesenchymal NMuMG clones, which would make boundary determination difficult 
using the markers we had chosen (E-cadherin and collagen). After removal of the 
inserts in which the 2 cell types were allowed to attach overnight, they were cultured 
for a further 3d. Treatment with TGFE induced a clear transgression of 3T3 cells into 
the epithelial zone following boundary formation (Figure 6). The activation of 
fibroblasts was also evident in the mesenchymal compartment, where cellular 
elongation and increased collagen expression were evident. In contrast, IGFBP-5 
induced a more rounded phenotype to the mesenchymal cells and, although they were 
making abundant collagen, the boundary remained intact. When administered with 
TGFE, IGFBP-5 was again able to inhibit the activation of fibroblasts induced by 
TGFE and thereby prevent disruption of the boundary between the epithelial and 
mesenchymal cells.   
In order to begin to assess the relevance of these findings to metastasis, we undertook 
immunohistochemical studies to determine IGFBP-5 expression in breast cancer 
biopsy tissue microarrays. IGFBP-5 expression was examined in the nucleus, 
cytoplasm and plasma membrane individually. Whilst no relationships were evident 
for IGFBP-5 expression in the plasma membrane or cytoplasm, high IGFBP-5 
expression in the nucleus was associated with increased disease-free intervals when 
compared to those with low IGFBP-5 nuclear expression (p=0.004, 93 v 83 months 
respectively). In particular, high expression of IGFBP-5 was associated with 
significant increases in disease-free periods in patients who subsequently received 
chemotherapy (p=0.031, 87 v 77 months), but not in those who did not (Figure 7). 
Additionally, this relationship between disease-free survival and expression of 
IGFBP-5 was evident in patients with high levels of apoptosis (p=0.002, 84 v 100 
months in low and high IGFBP-5 expressers respectively) but not in those with low 
levels of apoptosis. 
 
Discussion. 
NMuMG cells are able to form luminal, polarised structures similar to the normal 
mammary alveolar structure, (Swamydas et al. , 2010). Our studies confirmed 
previous findings (Maeda, Johnson, 2005) that NMuMG cells can be separated into 
stable clones with either epithelial or mesenchymal characteristics. We now 
demonstrate, for the first time, the responses of the mesenchymal clones to various 
growth factors. We generated three independent clones for both epithelial and 
mesenchymal cells with almost identical characteristics for clones of the same cell 
type (although there are subtle differences, for example in the number of epithelial 
cells killed by TGFE). Both epithelial and mesenchymal cells are stable in passage 
for more than 12 months and we believe that they represent a valuable and novel tool 
for comparing both EMT and MET in the same cell line.  
IGFBP-5 and epithelial cell adhesion and survival 
We recently identified a novel role for IGFBP-5 in the induction of epithelial cell 
adhesion and spreading which could play an important part in the prevention of 
metastasis and/or limit fibrosis (Sureshbabu, Okajima, 2012). In this study, we now 
also demonstrate this effect in a normal mouse mammary gland epithelial cell, as well 
as describing the ability of IGFBP-5 to antagonise the disruptive actions of TGFE. 
The adhesion of epithelial cells induced by IGFBP-5 was particularly evident in the 
presence of collagen or fibronectin, components of the mesenchymal matrix but was 
smaller in magnitude in the presence of laminin, the major component of the epithelial 
basement membrane. Thus, this action of IGFBP-5 would be exaggerated during 
exposure of epithelial cells to a mesenchymal environment, such as occurs during the 
tissue disruption evident in wound-healing or metastasis. Similar alterations in the 
response of both IGFBP-3 and IGFBP-5 in the presence of laminin or fibronectin 
have been described previously (McCaig et al. , 2002, Sureshbabu, Okajima, 2012). 
Although IGFBP-5 significantly extended epithelial cell survival, initially by driving 
cell adhesion to the substratum, it ultimately induced the formation of spheroids 
where, presumably, the forces involved in cell-cell contact were stronger than the cell-
substratum interaction and thus became the major determinant of phenotype. This 
response of the epithelial cells was similar to the effect of IGFBP-5 in MCF-7 breast 
cancer cells, where IGFBP-5 induced adhesion to the substratum. and maintained E-
cadherin expression and strong cell-cell contact (Sureshbabu, Okajima, 2012). What 
role might this response play? IGFBP-5 expression is increased in the brain during 
hypoxia (O'Donnell et al. , 2002) in Crohn’s disease (Zimmermann et al. , 1997) in  
atherosclerotic plaques and in senescing cells (Kim et al. , 2007). Survival in nutrient-
deprived/oxygen-depleted conditions is advantageous for tissue repair after injury, 
when vasculature is compromised and hypoxia is common and thus IGFBP-5 may 
play an important role in aiding epithelial cell survival and repair at these times 
(Johnson and Haun, 2009, Sureshbabu, Okajima, 2012).  
TGFE, in complete contrast to IGFBP-5, induced apoptosis of >80% of cells and 
induced EMT in the remaining cells, as evidenced by the complete loss of E-cadherin 
expression and the re-organisation of actin into stress fibres, confirming previous 
findings (Maeda, Johnson, 2005). Furthermore, when epithelial clones were treated 
with TGFE in the presence of IGFBP-5 both the apoptotic and EMT effects of 
TGFE were considerably reduced, though not ablated. Such antagonism of TGFE 
actions would again support a pro-survival action of IGFBP-5 in the epithelium. 
Effects of IGFBP-5 on adhesion and survival of mesenchymal cells 
When the actions of IGFBP-5 were examined on mesenchymal NMuMG cells or 
classical 3T3 fibroblasts, IGFBP-5 induced a striking inhibition of their adhesion to 
the substratum, in complete contrast to its effects upon epithelial cells. However, this 
lack of adhesion was somewhat artefactual, since the cells began to form small 
spheroids, apparently demonstrating a preference for cell-cell contact rather than cell 
substratum interactions (similar to that observed in the epithelial clones). This could 
be interpreted as a more epithelial characteristic, suggestive of an induction of MET. 
Whilst we would have liked to investigate this possibility by, for example, examining 
E-cadherin expression in these mesenchymal clones this proved impossible because 
the poor adhesion of the spheroids to the substratum meant that any 
immunohistochemical approach (involving multiple washes) resulted in the loss of all 
of the spheroids. Once again however, these actions of IGFBP-5 were in complete 
contrast to those of TGFE and, importantly, IGFBP-5 was able to completely 
antagonise the actions of TGFE on mesenchymal cells when they were administered 
together. 
Effects of IGFBP-5 on wound closure 
IGFBP-5 enhanced epithelial cell wound closure, whereas TGFE induced the 
opposite effect and, when administered in combination, IGFBP-5 was able to partially 
inhibit this action of TGFE. In mesenchymal cells (both NMuMG cells and 3T3 
cells) the opposite was evident, where TGFE increased wound closure, whereas 
IGFBP-5 antagonised this effect. 
Taken together, these results suggest that IGFBP-5 can inhibit the pro-fibrotic/pro-
metastatic actions of TGFE, both in terms of the effects of TGFE on epithelial cells 
(pro-apoptotic, induction of EMT) and mesenchymal cells (pro-adhesion, pro-
migratory). However, there is undoubtedly a pro-fibrotic response to IGFBP-5, based 
upon a number of published studies (Pilewski et al. , 2005, Yasuoka, Jukic, 2006a, 
Yasuoka, Zhou, 2006b). So, how might these apparently contradictory findings be 
reconciled? We believe our studies on epithelial-mesenchymal boundaries shed some 
light on this. IGFBP-5 clearly inhibited the disruptive effects of TGFE on the 
maintenance of epithelial-mesenchymal boundaries. IGFBP-5 has also been shown to 
increase the production of laminin-1 a major constituent of the epithelial basement 
membrane which aids in re-enforcement of the boundary (Abrass and Hansen, 2010). 
If we take into account the fact that IGFBP-5 is expressed in a number of tissues 
during injury or remodelling such as hypoxia in the brain, atherosclerotic plaques and 
involution of the mammary gland (Tonner et al. , 2002), then it is conceivable that 
IGFBP-5 produced by injured/dying epithelial cells, induces spreading/adhesion of 
neighbouring cells to provisional matrices or mesenchymal environments (to which 
they would not normally be exposed). This would allow more effective 
maintenance/repair of the epithelial barrier. At the same time, by promoting collagen 
and fibronectin production in the mesenchymal compartment, IGFBP-5 would support 
a “back-up” scar tissue response which would be present until epithelial repair was 
achieved. IGFBP-5 would, therefore, be able to support a controlled fibrotic response, 
rather than the massive and typically unresolved fibrotic scarring evident when 
TGFE is active. Thus, although IGFBP-5 is up-regulated in fibrosis (Feghali and 
Wright, 1999), this may reflect a positive repair strategy by epithelial tissues.  
Precisely how IGFBP-5 acts remains uncertain. Our studies were almost exclusively 
done in the absence of exogenous IGF-I, although we cannot rule out endogenous 
production of IGFs by the cells. However, our studies in MCF-7 cells included the use 
of a mutant form of IGFBP-5 which could not bind to IGFs (Allan et al. , 2006) and 
this was fully active in inducing adhesion and inhibiting migration (Sureshbabu, 
Okajima, 2012) suggesting that the actions of IGFBP-5 are indeed IGF-independent. 
We found no evidence that IGFBP-5 could inhibit the actions of TGFE1 on its 
receptor or immediate downstream signal via Smad2/3. These results are consistent 
with a previous study which showed that IGFBP-3 but not IGFBP-5 could influence 
Smad signalling (Fanayan et al. , 2002). Our previous study identified a novel 
interaction of IGFBP-5 with D2E integrins which was required for adhesion and an 
Akt-induced survival pathway (via integrin- rather than via PI-3 kinase). The fact that 
none of the classical signalling pathways appeared to have a major role in the 
adhesive action of IGFBP-5 is consistent with our previous findings, although it is at 
odds with the activation of MAPK by IGFBP-5 along with stimulation of collagen 
and fibronectin production in another study (Yasuoka et al. , 2009). However, the 
induction of fibronectin and collagen production by IGFBP-5 supports, rather than 
inhibits, the actions of TGFE and this suggests that IGFBP-5 functions in at least 2 
ways in mesenchymal cells. This mechanism of action resembles that of members of 
the CCNs, a family of proteins structurally-related to IGFBP-5, which involves 
interactions of integrins with the extracellular matrix (Leask and Abraham, 2006). 
IGFBP-5 and cancer 
So what of the associations of IGFBP-5 with cancer? Early studies identified 
increased IGFBP-5 expression in tumours and led to the proposal that IGFBP-5 was 
pro-metastatic (Hou, Zhang, 2009, Huynh, 1998, McGuire, Hilsenbeck, 1994, Mita, 
Zhang, 2007, Pekonen, Nyman, 1992). However, our data, along with other recent 
reports, suggest that IGFBP-5 is protective. For example, IGFBP-5 expression has 
recently been shown to be associated with increased survival times in breast cancer 
patients as well as being responsible for maintaining sensitivity to tamoxifen (Ahn et 
al. , 2010). In addition, overexpression of IGFBP-5 in MCF-7 xenografts inhibited 
tumour development in mice (Ahn, Elwi, 2010) whilst recent studies have 
demonstrated a tumour suppressor role for IGFBP-5 in ovarian cancer cells (Rho et al. 
, 2008) in osteosarcoma (Su et al. , 2011) and in breast cancer after foetal alcohol 
exposure (Polanco et al. , 2010). An intriguing relationship between IGFBP-5 and 
tumour dormancy has also been described. Genome-wide transcriptional analysis 
identified a small cohort of genes, of which IGFBP-5 was one, which were up-
regulated in dormant tumours of breast carcinoma, glioblastoma, osteosarcoma, and 
liposarcoma.  (Almog et al. , 2009, Satchi-Fainaro et al. , 2012).Our own observations 
of increased time to recurrence of breast cancer in individuals with high expression of 
IGFBP-5 add further weight to an anti-metastatic role for IGFBP-5. The fact that the 
relationship was evident for nuclear expression of IGFBP-5 is intriguing as IGFBP-5 
has a nuclear localisation signal and nuclear actions of IGFBP-5 have been described. 
Although these remain the subject of debate (Jurgeit et al. , 2007) this intra-nuclear 
role has been reported to be pro-apoptotic (Lee et al. , 2004) and thus may be another 
mechanism by which IGFBP-5 increases survival of breast cancer patients. . Why the 
role of IGFBP-5 should be most evident in those patients who undergo chemotherapy 
compared with those who do not, also requires explanation. For example, is the action 
of IGFBP-5 more effective in more aggressive tumours, those which typically require 
chemotherapy?  
 In summary, IGFBP-5 plays an important role in the epithelial cell response to 
injury/insult by inducing adhesion of epithelial cells to the provisional matrix and 
enhancing epithelial wound closure, in order to maximise the efficiency of barrier 
repair. At the same time, IGFBP-5 enhances deposition of scar tissue by mesenchymal 
cells but prevents their transgression into the epithelial compartment, partly by re-
enforcement of the epithelial barrier and partly by inducing an MET-like response and 
decreasing migration potential of mesenchymal cells. As such IGFBP-5 may be an 
important regulator of the pro-fibrotic and pro-metastatic actions of TGFE and could 
thus offer alternative routes to the generation of anti-fibrotic and anti-metastatic 
agents.  
 
 
Materials and Methods 
Production of recombinant IGFBP-5.  
Wild type IGFBP-5 was produced as described previously (Allan et al. , 2002, Shand 
et al. , 2003).  
Generation of adenovirus containing IGFBP-5 
This was performed exactly as described previously (Sureshbabu, Okajima, 2012) 
 
Cell culture 
NMuMg cells, a mouse mammary epithelial cell line, were obtained from ECACC 
(Cat No: 94081121). They were cultured in DMEM supplemented with 2mM 
glutamine, pencillin (5.0 U/ml) streptomycin (5mg/ml) insulin (10ȝg/ml) and 10% 
fetal bovine serum. Insulin was omitted from the medium for all experiments in which 
a response to IGF-I was to be determined. 
 
NIH 3T3 cells (ATCC no: CRL-1658) were cultured in DMEM with 2mM glutamine, 
penicillin (5.0 U/ml), Streptomycin (5mg/ml), and 10% FBS.  
Establishment of NMuMG clones: 
The NMuMG clones were established by limiting dilution of the original parent 
population of NMuMG cells . Generating two distinct cell types, one (epithelial) in 
which cell:cell adhesion was strong another (mesenchymal), where the cells showed 
little interaction..   
Determination of optimum concentrations for adenoviral infection of cells: 
Replication-deficient adenovirus containing the IGFBP-5 gene was used to infect 
NMuMG cells with a null adenovirus serving as a negative control. 
 
After trypsinisation, NMuMG cells were washed in serum-free DMEM. The cells 
were then infected with adenovirus in the wells of a 6-well tissue culture plate pre-
coated with 1 µg/ml of collagen to support the adhesion of the NMuMG cells in the 
absence of serum. Plates were cultured for 3 h, followed by supplementation with 10 
% FCS (to aid survival), followed by overnight incubation. The following day the 
cells were trypsinised, washed, counted and added to 24-well plates and cultured at 37 
C in 95% air/5%CO2. Medium from the wells was collected every day, for the 
determination of the IGFBP-5 concentration by Enzyme Linked Immunosorbent 
Assay (ELISA) to determine appropriate infection levels. 
 Enzyme Linked Immunosorbent Assay (ELISA) 
ELISA (IGFBP-5 Mouse ELISA Kit, aE00693,) was performed to determine the 
concentration of the IGFBP-5 produced from the adenoviral infected NMuMG cells 
exactly according to the manufacturer’s instructions (Abcam, Cambridge UK).  
Cell adhesion:  
Various concentrations of IGFBP-5, TGFE, IGF-I and insulin were prepared in 0.1% 
BSA: DMEM. The treatments (as described in the Results sections) were added to 96 
well plates. 3x 10
4
 NMuMG epithelial clones, mesenchymal clones or 3T3 cells, also 
in 0.1%BSA: DMEM, were added to triplicate wells. Plates were then cultured for 
either 30min or overnight at 37°C in a 5% CO2 atmosphere. The cells were then 
photographed, after which the medium was removed and cells were fixed with 100 µl 
of 4% (w/v) paraformaldehyde in phosphate buffer saline (PBS) for 20min at room 
temperature, After staining with crystal violet, and washing, the absorbance was 
determined at 540 nm.  
Cell signalling studies:  Inhibition assays: 
To examine the possible intracellular signalling pathways of IGFBP-5 and TGFE, 
various kinase inhibitors were added to 96-well plates containing 3x10
4
 cells in 
DMEM containing 10% serum, in the presence or absence of IGFBP-5 or TGFE and 
cultured for 24h, after which cells were fixed and stained with crystal violet. Final 
concentrations of the inhibitors used were LY-294,002 (5 µM), PD98,059 (25 µM), 
SB203,580 (1 µM) UO126 (10 µM) A83.01 (10 µM) and SB431542 (10 µM).  
Control wells contained an equivalent concentration of DMSO. 
WST-1 assay 
To determine metabolic activities, at the end of the culture period, WST-1 reagent 
(5ul/well) was added to 96-well plates and culture continued for 1 h before the 
absorbance was read at 450nm. 
Western immunoblotting. 
NMuMG Cells grown to 80% confluency on 12 well plates were treated with either 
TGF-ȕ1 (10ng/ml) alone, IGFBP-5 (10Pg/ml) alone or TGF-ȕ1 plus IGFBP-5 for 30 
minutes before harvesting. Cells were harvested in sample buffer containing (125mM 
Tris-Base (pH6.7), 0.5mM Na4P2O7, 1.25mM EDTA, 1.25% (v/v) glycerol, 0.5% 
(w/v) SDS, 25mM 1.4-Dithiothreitol (DTT) and 0.02% (w/v) bromophenol blue) and 
were subjected to SDS-PAGE and Western blotting as previously described  
(Alderton et al. , 2001). Resolved proteins were Western blotted with anti-phospho-
smad 2 (Cell signalling, code 3108P )and visualised using the enhanced chemi-
luminescence method. 
Immunofluorescence staining: 
Cells were cultured in 8-well chamber slides. At the end of the culture period, 
medium was removed from the wells by inverting the chamber slides and cells were 
fixed with 200 µl of 2% (w/v) paraformaldehyde in PBS for 10 min followed by 
permeabilization with 200 µl of 0.5% triton X-100 in PBS for 15 min at room 
temperature. Non-specific staining was diminished by incubating with 10% heat-
inactivated serum, derived from the species in which the second antibody was 
produced. Cells were incubated with 200ul of mouse anti-E-cadherin (5ug/ml) 
(Invitrogen, Cat no: 334000) anti-collagen (1:500) (Abcam, Cat .No: ab88147) or 
anti-fibronectin (1:500) (Abcam, Cat No: ab23750). This was followed by 1 h 
incubation with secondary antibody labelled with either Texas red or FITC (1:200). F-
actin was detected using either rhodamine- or FITC-phalloidin (Biotium, U.S.A.). 
Slides were covered with antifade DAPI nucleic acid mountant (Molecular Probes, 
Invitrogen, U.S.A). The slides were visualized with a Nikon TE300 (Nikon, Kingston 
upon Thames, UK) inverted epifluorescence microscope using x40 or x100 objectives 
with oil immersion and a Hamamatsu CCD camera (Hammamatsu Photonics, 
Welwyn Garden City, UK) controlled by Metamorph software (Molecular Devices 
Palo Alto, CA, USA) or a Leica DMIRB microscope (Leica Microsystems (UK) Ltd 
Milton Keynes, Bucks, UK) using a x40 objective (Leica N PLAN 40x/0.55 NA 
CORR PH2  0-2/C) a x10 objective (Leica N PLAN 10x/0.25 PH1 -/A 5.8) or a x5 
objective (Leica N PLAN 5x/0.12 PH0 -/A ). Images were captured on a Leica DC200 
(DMIRB) and analysed using a Leica Q550 Image Analysis Workstation (v2.2.1) 
combined with Leica Qwin Software for image acquisition. 
The images were optimized using Adobe Photoshop. Composite pictures were taken 
and adjustments in brightness and contrast were applied equally across all images to 
prevent the introduction of any bias. 
Migration assays 
The cell migration assay was carried out in 24-well plates using ibidi 2-chamber 
inserts (Thistle Scientific Ltd, Glasgow). Chambers were added to the wells and then 
seeded with, typically 30,000-50,000 cells to achieve a confluent monolayer 
overnight. Treatments were also added at this time. After overnight culture the inserts 
were removed to reveal 2 patches of cells separated by a 500um gap. Fresh medium 
containing treatments was added and migration allowed to proceed until stopped by 
fixing in 4% PFA. Cells were stained with crystal violet and images taken for analysis 
using ImageJ software. 
Boundary assays 
Boundary assays utilised the same ibidi chambers but each chamber received different 
cells (epithelial in one and mesenchymal in the other). After overnight culture the 
inserts were removed and the culture continued for a further 24h to allow boundary 
formation to occur. Exogenous treatments were then added and cells cultured for a 
further 48h, after which they were fixed and stained for E-cadherin (epithelial marker 
and collagen (mesenchymal marker). 
Patients and tissue microarray (TMA) construction  
A total of 371 patients were included in this study, all presenting with invasive breast 
cancer between 1995 and 1998 and recruited in the Greater Glasgow area. Available 
clinico-pathological data for each patient included age, tumour grade, tumour invasive 
grade, lymph node status, oestrogen receptor (ER) status, HER2 status and what 
therapy the patient had received. The data was retrieved from the NHS electronic 
patient notes by a member of the health care team as this was a retrospective study.  
Recurrence was determined when the patients returned to clinic with symptoms and 
recurrence was evident,, or on a routine follow-up appointment when a recurrence 
was identified. 
TMAs were already available for use in this study. These were constructed using 
0.6mm
2
 cancer tissue cores taken from representative areas of tumour from each 
patient. All blocks were constructed in triplicate containing three individual tumour 
cores taken from the same embedded tissue sample. 
Immunohistochemistry 
Immunohistochemistry was used to assess protein expression in the tissue. TMAs 
were rehydrated in graded alcohols followed by heat induced antigen retrieval in 
EDTA buffer pH9 for 5 minutes in a pressure cooker. Endogenous peroxidase was 
quenched with 3% hydrogen peroxide for 20 minutes and non-specific binding of 
primary antibody was blocked by incubation of TMAs in 5% horse serum in 1X Tris-
buffered saline (TBS) for 30 mins. Tissue was then incubated in 5ug/ml IGFBP5 
mouse monoclonal antibody (MAB875, R&D systems, USA) overnight at 4°C. Slides 
were incubated in Dako EnVision™ secondary antibody (Dako, Denmark) for 30 
minutes and staining was detected using the chromogen 3,3’-diaminobenzidine 
(DAB) for 5 minutes. Tissue was then counterstained with haemotoxylin, dehydrated 
in graded alcohols and xylene and mounted with glass coverslips using DPX.  
Scoring 
Protein expression was assessed using the weighted histoscore method (Kirkegaard et 
al. , 2006). This method first grades the intensity of staining from 0 (negative) to 3 
(strong) and then multiplies the grade by the percentage of tumour cells within each 
category. The final histoscore varies between 0 (minimum) and 300 (maximum) and 
is averaged for the triplicate samples.  
Statistical analysis was performed using SPSS version 19.0 for Windows. Univariate 
outcome analyses were conducted by Kaplan-Meier methods, using the log-rank test 
to compare outcome between patients grouped according to clinico-pathologic 
parameters and high/low protein expression.  Disease-free survival rates were 
obtained using Kaplan–Meier method. The log-rank test was used to compare survival 
curves between subgroups.  
 
Patient approval 
Ethical approval was gained from the local ethics committee. Due to the retrospective 
nature of the study patient consent was not required. 
 
Statistical analysis 
In vitro study data were analysed using Analysis of Variance followed by 
Bonferroni’s post-hoc test.  
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Titles and legends to figures: 
Figure 1.  Characterisation of NMuMG epithelial and mesenchymal clones. 
Panel A: Bright field images, demonstrating the difference in phenotype of the cells. 
Bar = 100um. Panel B: expression of F-actin, at the plasma membrane in epithelial 
clones and as stress fibres in the mesenchymal clones. Bar represents 50um. Panel C. 
Epithelial cells exclusively express E-cadherin whereas mesenchymal cells whereas 
mesenchymal cells do not. Bar represents 100um. Panel D. Mesenchymal cells 
express collagen whereas epithelial cells do not. Bar represents 25um. Panel E: 
Expression of fibronectin is greatly increased in mesenchymal cells. Bar represents 
20um. Panel F: When co-cultured, the cells organise into epithelial colonies 
surrounded by mesenchymal cells. Bar represents 100um. Panel G: In 3D culture, 
epithelial cells form regular spheroids (visualised via e-cadherin expression) whereas 
mesenchymal cells form elongated structures expressing fibronectin. Finally, when 
co-cultured in 3D, spheroids are connected to each other by duct-like structures. Bar 
represents 100um. 
Figure 2.  TGFE induces apoptosis in epithelial cells but survival in mesenchymal 
cells. IGF-I and insulin support survival in both cell types.  
Panel A. Cell survival response to growth factors in epithelial and mesenchymal 
clones of NMuMG cells. Cells were seeded in the presence of 10% serum overnight 
to allow attachment, after which the cells were washed to remove the serum and 
cultured in the presence of various growth factors in 2% FCS DMEM for 2d. Cells 
were then fixed, stained with crystal violet and absorbance values determined at 
540nm. Values are means + SEM of 6 observations. ** p<0.01, *** p<0.001 
compared with control cells (ANOVA followed by Bonferroni’s test for multiple 
comparisons). 
Panel B: TGFE induces apoptosis of NMuMG epithelial clones (dying cells evident 
as dark, shrunken spheroids but EMT is evident in the surviving cells which show 
little cell-cell interaction. Actin re-arrangement is evident after TGFE treatment with 
stress fibre formation, which contrasted with the expression of F-actin in the plasma 
membrane of control cells. Bar represents 25um. 
Panel C. TGFE induces cell death and down-regulation of E-cadherin expression. 
Epithelial cells were cultured with TGFE with or without BMP-7 for 3d and then 
fixed and stained for E-cadherin (green) and DAPI (blue).The effects of TGFE were 
completely abolished by concurrent treatment with BMP-7, a TGFE inhibitor. Bar 
represents 50um. 
 
Figure 3: IGFBP-5 enhances adhesion and survival of epithelial cells but decreases 
adhesion of mesenchymal cells.  
Panel A. Treatment with IGFBP-5 increases adhesion of NMuMG epithelial cells. 
NMuMG cells (in 0.1%BSA DMEM ) were seeded into 96-well plates coated with 
laminin, fibronectin or collagen. After 30 minutes culture at 37C, the plates were 
inverted, washed and fixed in 4% paraformaldehyde. They were then stained with 
crystal violet, photographed and absorbances were determined at 540nm. Bar 
represents 100um. 
Panel B. Quantification of the results of the study shown in Panel A. Values are 
means + SEM of 6 observations. ***, p<0.001 compared with control cells (ANOVA 
followed by Bonferroni’s test for multiple comparisons). 
Panel C. NMuMG cells were trypsinised and seeded into 96-well plates at 4 x10
5
 
cells/ml in 0.1%BSA DMEM along with insulin (10ug/ml), IGF-I, (100 ng/ml), 
IGFBP-5 (10ug/ml) TGFE (10ng/ml) or  combinations of these. After 24h culture at 
37 C, cells were photographed under bright field conditions. Bar represents 100um. 
Panel D: Quantification of spheroid numbers and size from experiment described in 
Panel C. Spheroids were classified as having a minimum diameter of 25Pm (typically 
8-10 cells). Values are means + SEM of 4 observations. * p<0.05, *** p< 0.001 
compared with control. Data for TGFEare not shown as no spheroids were evident. 
Panel E: IGFBP-5 antagonises the apoptotic effect of TGFE on epithelial cells. 
Epithelial cells were infected with either adenovirus expressing IGFBP-5 or the null 
vector and cultured for 24h to allow expression of IGFBP-5 to be established. Cells 
were then trypsinised and 4x10
5
 epithelial cells were seeded into 96-well plates in 
DMEM containing 10% serum. After overnight culture to allow attachment, and to 
permit IGFBP-5 secretion to become established, TGFE1 (0.1-3 ng/ml) was added to 
the wells. After 3d the cells were fixed and stained with crystal violet and absorbances 
determined at 540nm. Values are means + SEM. * p<0.01 compared with TGFE 
alone. 
Panel F. IGFBP-5 reduces the epithelial-mesenchymal rearrangement induced by 
TGFE in epithelial cells. Epithelial cells were infected with either adenovirus 
expressing IGFBP-5 or the null vector and cultured for 24h to allow expression of 
IGFBP-5 to be established. Cells were then trypsinised and 4x10
5
 epithelial cells were 
seeded into chamber slides  in DMEM containing 10% serum. After overnight culture 
to allow attachment, and to permit IGFBP-5 secretion to become established, TGFE1 
(0.1-3 ng/ml) was added to the wells. After 3d the cells were fixed and stained with 
phalloidin to reveal actin filaments in red (upper panel) or with anti-E-cadherin in 
green (lower panel). Nuclei were stained blue with DAPI. Bar represents 25um. 
Panel G: Treatment with IGFBP-5 decreases adhesion of NMuMG mesenchymal 
cells. Mesenchymal cells (in 0.1%BSA DMEM ) were seeded into 96-well plates 
coated with laminin, fibronectin or collagen. After 30 minutes culture at 37C, the 
plates were inverted rinsed and fixed in 4% paraformaldehyde. They were then 
stained with crystal violet, photographed and absorbances determined at 540nm. 
Panel H. Quantification of the results of the study shown in Panel G. Values are 
means + SEM of 6 observations. ***, p<0.001 compared with control cells (ANOVA 
followed by Bonferroni’s test for multiple comparisons). 
Panel I: TGFE induces activation of mesenchymal cells whereas IGFBP-5 induces 
de-adhesion, an action which overrides the effect of TGFE. TGFE induces a dose-
dependent activation of mesenchymal cells, seen as cell elongation and swirling 
patterns. IGFBP-5 induces a dose-dependent de-adhesion and formation of cell 
clumps (arrows).  
Panel J: When TGFE and IGFBP-5 were administered together, the effect of IGFBP-
5 predominated. 
 
 Figure 4.  
Panel A. IGFBP-5 induces the formation of epithelial spheroids and its actions are 
unaffected by various kinase inhibitors. NMuMG epithelial cells were trypsinised and 
seeded into 96-well plates at 4 x10
5
 cells/ml in 0.1%BSA DMEM along with various 
kinase inhibitors (see Methods for concentrations) with or without IGFBP-5 
(10ug/ml). Control wells received equivalent concentrations of DMSO. After 24h 
culture at 37 C, cells were photographed under bright-field conditions. 
Panel B. TGFE induces epithelial cell death and its actions are prevented by 
inhibitors of the Smad pathway. NMuMG epithelial cells were trypsinised and seeded 
into 96-well plates at 4 x10
5
 cells/ml in DMEM containing 10%serum along with 
various kinase inhibitors (see Methods for concentrations) with or without TGFE 
(10ng/ml). Control wells received equivalent concentrations of DMSO. After 24h 
culture at 37 C, cells were fixed, stained with crystal violet and absorbances 
determined at 540nm. Values are means + SEM of 6 observations. ***, p<0.001 
compared with respective control wells (ANOVA followed by Bonferroni’s test for 
multiple comparisons). 
Panel C TGFEincreases phosphorylation of Smad 2/3 in epithelial cells, whereas 
IGFBP-5 has no effect. NMuMG epithelial cells were seeded into 12-well plates 
overnight. They were then washed and treated with TGFEwith or without IGFBP-5 
for 30 min. Cells were harvested and subjected to Western blotting for phospho- 
Smad 2/3. Representative blots are shown on the left and quantitative analysis using 
Image J is shown on the right. M, molecular weight markers; C, control; T, TGFE1; I, 
IGFBP-5. Values are means + SEM of 5 observations. ** p<0.01 compared with 
control cells. 
Panel D. IGFBP-5 induces de-adhesion of NMuMG mesenchymal cells and is 
unaffected by various kinase inhibitors. NMuMG mesenchymal cells were trypsinised 
and seeded into 96-well plates at 4 x10
5
 cells/ml in 0.1%BSA DMEM along with 
various kinase inhibitors (see Methods for concentrations) with or without IGFBP-5 
(10ug/ml). Control wells received equivalent concentrations of DMSO. After 24h 
culture at 37 C, cells were fixed, stained with crystal violet, photographed and 
absorbances determined at 540nm.  
Panel E: Quantitative analysis of data derived from the study shown in Panel D. 
Values are means + SEM of 6 observations. ***, p<0.001 compared with respective 
control wells (ANOVA followed by Bonferroni’s test for multiple comparisons). 
 
Figure 5. IGFBP-5 enhances wound closure in NMuMG epithelial cells but inhibits it 
in NMuMG mesenchymal cells, thereby antagonising the actions of TGFE. 
Panel A: Epithelial cells were seeded into ibidi 2-chamber inserts to produce 
confluent monolayers overnight. The inserts were then removed and the cells cultured 
in DMEM containing 10% serum with or without TGFE (2ng/ml) or IGFBP-5 
(10ug/ml) or a combination of both. Migration was allowed to proceed for 24h and 
the cells were then fixed, stained with crystal violet and photographed. Bar represents 
250um. 
Panel B. Mesenchymal cells were seeded into ibidi 2-chamber inserts to produce 
confluent monolayers overnight. The inserts were then removed and the cells cultured 
in DMEM containing 10% serum with or without TGFE (2ng/ml) or IGFBP-5 
(10ug/ml) or a combination of both. Migration was allowed to proceed for 24h and 
the cells were then fixed, stained with crystal violet and photographed. Bar represents 
250um. 
Panels C and D: Quantitative analysis of the studies described in panels A and B, 
respectively. Values are Means +SEM of 6-8 observations. * p<0.05, *** P< 0.001 
compared with control. 
a 
p< 0.01 compared with TGFE alone. 
  
Figure 6: TGFE induced mesenchymal cell invasion of the epithelial cell layer: 
inhibition by IGFBP-5.  
NMuMG epithelial cells were infected with IGFBP-5 adenovirus or null adenovirus 
and after overnight culture, the cells were trypsinised and 3x10
4 
cells were seeded into 
one chamber of an ibidi 2 chamber insert in a 24-well tissue culture plate. 2x10
4
 3T3 
cells were seeded into the opposite chamber. After overnight culture, to allow 
adhesion, the inserts were removed and the cells cultured for a further 3d in the 
presence or absence of TGFE (2ng/ml). Cells were then fixed and stained for E-
cadherin (red) or collagen (green). Bar represents 100um. 
 
Figure 7. High expression of IGFBP-5 increase disease-free intervals in patients 
receiving chemotherapy or with high TUNEL expression. Kaplan–Meier survival 
plots showing the effect of expression of nuclear IGFBP-5 on recurrence of breast 
cancer in patients who did or did not receive chemotherapy and in patients with high 
or low TUNEL expression. 
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